Summary
Grifols’ board has approved a plan to offer a minority stake in its U.S. biopharma business in an initial public offering on the U.S. market. The company said the proceeds are intended to cut debt and bolster the group’s balance sheet while preserving majority ownership and operational authority over the unit. The announcement pushed Grifols shares up more than 2% on Wednesday.
Deal structure and strategic rationale
The Barcelona-based healthcare group will list a minority interest in the U.S. biopharma unit in the United States but will retain majority ownership and direct operational control. Management framed the transaction as a way to strengthen the group’s financial position and to provide capital to support strategic growth initiatives.
Grifols described the U.S. business as a "fully integrated and self-sufficient model," operating across the full value chain from plasma collection through to distribution. The unit currently manages almost 300 donation centers across 40 states and employs more than 14,000 people, according to the company.
Governance and investor positioning
The company said the U.S. unit will be set up with its own board of directors and a dedicated management team. Grifols noted that this structure is intended to align the business with investor demand for "pure-play U.S. plasma" exposure and to simplify the overall capital structure of the group.
In its statement, Grifols said the proposed transaction "reinforces Grifols’ self-sufficiency vision, making it the only U.S. player in the sector that does not depend on other markets."
Global context and parallel projects
The IPO announcement comes as Grifols advances similar self-sufficiency initiatives in other regions. The company said it supported Egypt in becoming the sixth country worldwide to reach plasma-derived medicine self-sufficiency; that project is positioned to gain EMA certification in 2025 and to serve as a regional export hub to Europe thereafter.
In Canada, Grifols referenced a partnership with Canadian Blood Services that has lifted immunoglobulin self-sufficiency from 15% to 33%, with a target of 50%. The company also noted a new fractionation facility in Montreal that is expected to start operations in 2028.
Market listings and conditions
Grifols employs over 23,800 people across more than 30 countries. The group’s class A shares are listed in Spain, while its non-voting class B shares trade on the Spanish market and on the U.S. NASDAQ.
The company cautioned that the IPO remains conditional on market conditions and regulatory approvals.
Implications for investors and markets
Investors will watch how the IPO is structured, the market reception to a U.S.-listed minority stake in a plasma business, and how proceeds are used to reduce leverage and support growth. The timing and completion of the offering will depend on prevailing market sentiment and regulatory clearances.